Research Status and Progress of Third-generation EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer
For patients with advanced non-small cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor (EGFR) mutations, guidelines prioritize the use of third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), which offer higher objective response rate (ORR), longer progression-fre...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2025-05-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2025.101.09 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850135394634432512 |
|---|---|
| author | Xue CHEN Yijia SUN Lihong ZHANG Bo JIANG |
| author_facet | Xue CHEN Yijia SUN Lihong ZHANG Bo JIANG |
| author_sort | Xue CHEN |
| collection | DOAJ |
| description | For patients with advanced non-small cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor (EGFR) mutations, guidelines prioritize the use of third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), which offer higher objective response rate (ORR), longer progression-free survival (PFS), and better quality of life. However, due to the low proportion of elderly patients enrolled in clinical trials, the existing evidence is insufficient to fully guide clinical practice. This review examines the efficacy and safety differences of third-generation EGFR-TKIs as monotherapy or in combination in the elderly NSCLC by integrating subgroup analyses or pre-specified research objectives from prospective and retrospective studies. The results show that third-generation EGFR-TKIs have comparable efficacy in elderly patients to younger populations and are well-tolerated. Although combination therapies may extend survival time, the associated increased toxicity necessitates careful risk-benefit assessment. |
| format | Article |
| id | doaj-art-3894e825c1944baaacfa8ab4d0d66d42 |
| institution | OA Journals |
| issn | 1009-3419 1999-6187 |
| language | zho |
| publishDate | 2025-05-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj-art-3894e825c1944baaacfa8ab4d0d66d422025-08-20T02:31:27ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872025-05-0128533434210.3779/j.issn.1009-3419.2025.101.09Research Status and Progress of Third-generation EGFR-TKIs
in Elderly Patients with Non-small Cell Lung CancerXue CHEN0Yijia SUN1Lihong ZHANG2Bo JIANG3Kunming Medical University, Kunming 650500, ChinaKunming Medical University, Kunming 650500, ChinaKunming Medical University, Kunming 650500, ChinaDepartment of Geriatric Oncology, the Third Affiliated Hospital of
Kunming Medical University, Kunming 650118, ChinaFor patients with advanced non-small cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor (EGFR) mutations, guidelines prioritize the use of third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), which offer higher objective response rate (ORR), longer progression-free survival (PFS), and better quality of life. However, due to the low proportion of elderly patients enrolled in clinical trials, the existing evidence is insufficient to fully guide clinical practice. This review examines the efficacy and safety differences of third-generation EGFR-TKIs as monotherapy or in combination in the elderly NSCLC by integrating subgroup analyses or pre-specified research objectives from prospective and retrospective studies. The results show that third-generation EGFR-TKIs have comparable efficacy in elderly patients to younger populations and are well-tolerated. Although combination therapies may extend survival time, the associated increased toxicity necessitates careful risk-benefit assessment.http://dx.doi.org/10.3779/j.issn.1009-3419.2025.101.09lung neoplasmsepidermal growth factor receptor-tyrosine kinase inhibitorsresearch statusresearch progress |
| spellingShingle | Xue CHEN Yijia SUN Lihong ZHANG Bo JIANG Research Status and Progress of Third-generation EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer Chinese Journal of Lung Cancer lung neoplasms epidermal growth factor receptor-tyrosine kinase inhibitors research status research progress |
| title | Research Status and Progress of Third-generation EGFR-TKIs
in Elderly Patients with Non-small Cell Lung Cancer |
| title_full | Research Status and Progress of Third-generation EGFR-TKIs
in Elderly Patients with Non-small Cell Lung Cancer |
| title_fullStr | Research Status and Progress of Third-generation EGFR-TKIs
in Elderly Patients with Non-small Cell Lung Cancer |
| title_full_unstemmed | Research Status and Progress of Third-generation EGFR-TKIs
in Elderly Patients with Non-small Cell Lung Cancer |
| title_short | Research Status and Progress of Third-generation EGFR-TKIs
in Elderly Patients with Non-small Cell Lung Cancer |
| title_sort | research status and progress of third generation egfr tkis
in elderly patients with non small cell lung cancer |
| topic | lung neoplasms epidermal growth factor receptor-tyrosine kinase inhibitors research status research progress |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2025.101.09 |
| work_keys_str_mv | AT xuechen researchstatusandprogressofthirdgenerationegfrtkisinelderlypatientswithnonsmallcelllungcancer AT yijiasun researchstatusandprogressofthirdgenerationegfrtkisinelderlypatientswithnonsmallcelllungcancer AT lihongzhang researchstatusandprogressofthirdgenerationegfrtkisinelderlypatientswithnonsmallcelllungcancer AT bojiang researchstatusandprogressofthirdgenerationegfrtkisinelderlypatientswithnonsmallcelllungcancer |